With Just a Month to Go, HRSA Releases First FY 2022 Manufacturer 340B Audit Result

Unichem Pharmaceuticals USA must repay 340B covered entities for overcharges found during an FY 2022 340B program compliance audit.

Generic drug manufacturer Unichem Pharmaceuticals USA must repay 340B covered entities for overcharges found during a 340B program compliance audit, the U.S. Health Resources and Services Administration (HRSA) said yesterday.

HRSA has been auditing five drug manufacturers per

Read More »

Advocates Urge Feds to Allow Distressed Rural Hospitals to Remain 340B Eligible

Financially distressed critical access hospitals should be allowed to keep their 340B drug discounts if they opt under a new federal law to downgrade into emergency hospitals to remain solvent, rural health advocates told CMS in comments on proposed rules to implement the law.

Congress and the White House should let financially distressed critical access hospitals keep their 340B drug discounts if they opt under a new law to downgrade into emergency hospitals to remain solvent, rural health advocates told federal health

Read More »

Financial Outlook Deteriorating for Nonprofit Hospitals in 2022 and Beyond, Credit Rating Agency Says

Mass General Brigham is among the nonprofit health systems that have reported significant financial pressure this year.

In its mid-year report released this month, Fitch Ratings predicts a “deteriorating” outlook for nonprofit hospitals and health systems through the remainder of 2022 and into 2023. This is primarily driven by the “macro headwinds” of high labor

Read More »

Exclusive: HRSA Hasn’t Posted a Limited Distribution Plan Notice to 340B Entities in Almost a Year. No One Outside of the Agency Knows Why.

HRSA has published no drug manufacturer limited distribution plan notices to 340B covered entities since mid-September 2021.

Last September, the U.S. Health Resources and Services Administration (HRSA) published a drug manufacturers’ notice to 340B covered entities that it was limiting distribution of a medicine that alleviates a side effect of HIV/AIDS treatment.

It was the

Read More »

Judge Orders HHS to Respond to Ruling Letting Health Center Challenge 340B Patient Definition

A federal appeals court gave South Carolina-based Genesis Health Care another chance to challenge the legality of the 340B drug pricing program's patient definition.

A federal district judge on Tuesday gave federal health officials a Sept. 22 deadline to respond to a higher court’s ruling last month that a South Carolina health center has the right to challenge the legality of the

Read More »

House GOP Lawmaker Reintroduces Bill to Collect and Report 340B Hospital Data

U.S. Rep. Bruce Westerman (R-Ark.) has reintroduced a bill that would create new reporting requirements for 340B disproportionate share (DSH), children’s, and free-standing cancer hospitals and their child sites.

U.S. Rep. Bruce Westerman (R-Ark.) has reintroduced a comprehensive health care bill he sponsored during the last session of Congress that would create new reporting requirements for 340B disproportionate share (DSH), children’s, and free-standing cancer hospitals and their

Read More »

Sixth Group of 340B Hospitals Sues HHS Over Medicare Drug Payment Cuts

New Orleans-based Ochsner Medical Center and six other 340B hospitals have sued in federal court to force HHS to immediately remedy illegal Medicare Part B drug payment cuts in place since 2018.

Correction, Friday, Aug. 26, 2022, 3:00 p.m. EDT—The original version of this article mistakenly said the hospital plaintiffs’ complaint stated that HHS improperly based 2020 and 2021 Medicare Part B drug payment cuts for 340B hospitals on a

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors